Targeting lactate metabolism to restore immune homeostasis: a precision therapeutic paradigm for rheumatoid arthritis

Lin Zheng, A Xinyu, Shiyu Ma, Bo Xu, Zheng Xiang, Boran Cao, Jun Shen, Xirui Xu, Yiwei Cheng, Lei Ran, Qi Shi, Yanqin Bian, Lianbo XiaoFrontiers in Immunology 2025 · DOI

This review article, published in Frontiers in Immunology, explores the emerging role of lactate—long dismissed as a mere metabolic waste product—as a central driver of inflammation and joint destruction in Rheumatoid Arthritis (RA). The authors propose a shift from symptom management toward "metabolic restoration" through precision targeting of lactate production, transport, and signaling.

TL;DR

Lactate acts as a pathogenic signaling molecule in the RA synovium, driving a "vicious cycle" of immune dysfunction and bone erosion. By targeting lactate metabolism—specifically through LDHA inhibitors and MCT transporters—clinicians may be able to restore immune homeostasis and provide personalized therapies for patients who fail to respond to conventional biologics.

What Problem Does This Paper Address?

Despite the success of biologics and JAK inhibitors, approximately 30–40% of RA patients do not achieve adequate clinical response. Current treatments primarily target downstream inflammatory cytokines (like TNF-α or IL-6) rather than the underlying metabolic triggers that sustain chronic inflammation.

The "synovial microenvironment" in RA is hypoxic and acidic, characterized by massive lactate accumulation. This paper addresses the need to understand how this metabolic reprogramming (the "Reverse Warburg Effect") fuels the transition from acute inflammation to a self-perpetuating chronic disease state. The goal is to move beyond "one-size-fits-all" treatments toward a precision medicine paradigm based on a patient’s unique metabolic profile.

Methods

As a comprehensive review, the paper synthesizes recent findings from immunometabolism, proteomics, and single-cell RNA sequencing. It focuses on three primary axes of lactate-driven pathology:

  1. Production: The role of Lactate Dehydrogenase A (LDHA) in converting pyruvate to lactate within synovial fibroblasts.
  2. Transport: The function of Monocarboxylate Transporters (MCT1 and MCT4) in shuttling lactate between cells.
  3. Epigenetics (Lactylation): A novel post-translational modification where lactate covalently attaches to lysine residues on histones, directly altering gene expression in immune cells.

Datasets

As this is a review article, it does not introduce a new primary dataset. Instead, it evaluates and summarizes data from:

  • Preclinical Models: Collagen-induced arthritis (CIA) models used to test LDHA and MCT inhibitors.
  • Clinical Biomarkers: Studies correlating synovial fluid lactate levels with Disease Activity Scores (DAS28).
  • Omics Data: Single-cell RNA sequencing and proteomic "lactylome" profiles of RA synovial tissues.

Key Insights and Ideas

  • The Reverse Warburg Effect: Unlike cancer cells that use glycolysis for their own growth, RA synovial fibroblasts (RASFs) act as "metabolic factories," producing and exporting lactate to "fuel" infiltrating T cells and macrophages, promoting an inflammatory phenotype.
  • Lactylation as a "Metabolic Code": The discovery of protein lactylation (specifically at H3K18) provides a direct link between a cell's metabolic state and its genetic output. In Th17 cells, high lactate levels trigger lactylation that promotes the production of pro-inflammatory cytokines.
  • The Vicious Cycle: Lactate isn't just a result of inflammation; it causes it. It stimulates angiogenesis (via VEGF), promotes bone-dissolving osteoclasts (via RANKL), and creates a physical barrier that prevents conventional drugs from penetrating deep into synovial tissues.
  • Therapeutic Synergy: The authors highlight that metabolic modulators (like LDHA inhibitors) can work synergistically with existing biologics, potentially lowering the required dose of toxic drugs while improving efficacy.

Key Results

  • LDHA Inhibition: Preclinical studies of the LDHA inhibitor FX-11 showed significant reductions in joint inflammation, cartilage destruction, and bone erosion in arthritis models.
  • MCT Targeting: Inhibiting MCT1 (via AZD3965) or MCT4 disrupts the lactate shuttle, effectively "starving" inflammatory immune cells and reducing their recruitment to the joint.
  • Patient Stratification: The paper proposes a decision tree for precision medicine. For example, patients with "High Lactate" phenotypes (serum lactate >4mM) are identified as prime candidates for LDHA inhibitor therapy, while those with "Fibrotic" phenotypes might require anti-fibrotic agents.

Limitations and Future Work

  • Systemic Toxicity: Lactate is essential for normal physiological functions in the brain, heart, and skeletal muscle. Developing joint-specific delivery systems (like the nanoparticle-based prodrugs mentioned) is critical to avoid systemic side effects.
  • Clinical Translation: Most evidence currently stems from preclinical animal models. Large-scale human clinical trials are needed to validate lactate-targeting drugs.
  • Long-term Safety: The effects of chronic metabolic intervention on the broader immune system remain unknown.
  • Biomarker Standardization: While lactate is a promising biomarker, the field needs standardized assays and reference ranges to accurately stratify patients in a clinical setting.

Summary updated

Abstract

The accumulation of lactate in synovial microenvironment of rheumatoid arthritis (RA) patients is closely correlated with disease activity, with elevated lactate levels serving as both biomarkers and pathogenic mediators in RA progression. In recent years, mounting evidence has demonstrated that lactate-driven metabolic reprogramming constitutes the central hub of the immune-metabolic-bone destruction axis in RA. The accumulation of lactate in the synovial microenvironment triggers a cascade of immunoregulatory effects, and these metabolic alterations create a self-perpetuating cycle of inflammation and tissue destruction, which represents the fundamental cause of RA chronicity. Therefore, lactate metabolism has been identified as a therapeutic target, opening new avenues for precision medicine approaches in RA treatment. Novel therapeutic strategies targeting lactate dehydrogenase A (LDHA) inhibitors, monocarboxylate transporters (MCTs), and enzymes that regulate lactylation have shown promising preclinical results. Furthermore, combination therapies pairing metabolic modulators with conventional biologics demonstrate synergistic effects in suppressing inflammatory pathways while improving drug penetration into synovial tissues. Additionally, patient stratification based on lactate metabolic profiles enables personalized treatment approaches. In summary, targeting lactate metabolism represents a paradigm shift in RA treatment from symptom management toward metabolic restoration. The integration of metabolic modulators with existing therapeutic regimens holds promise for achieving sustained remission and preventing long-term joint damage.
BibTeX
@inproceedings{zheng2025targeting,
  author = {Lin Zheng and A Xinyu and Shiyu Ma and Bo Xu and Zheng Xiang and Boran Cao and Jun Shen and Xirui Xu and Yiwei Cheng and Lei Ran and Qi Shi and Yanqin Bian and Lianbo Xiao},
  title = {{Targeting lactate metabolism to restore immune homeostasis: a precision therapeutic paradigm for rheumatoid arthritis}},
  booktitle = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1696932},
}
Figure